Strategic Partnering TegMine's collaboration with Boehringer Ingelheim and the development of a two-factor antibody system position the company for licensing or co-development deals with major pharma focused on antibody-drug conjugates for solid tumors.

Platform Advantage The TegMiner platform enables discovery of unique glycoprotein epitopes, creating a differentiated offering for pharma partners seeking novel ADC targets and potentially enabling joint research collaborations.

Scalable Collaboration With a lean team, TegMine will likely rely on CRO/CMO, manufacturing, and regulatory support to advance programs; business development opportunities include providing outsourced development services or end-to-end program partnerships.

Local Ecosystem Based in South San Francisco, the company benefits from proximity to leading biotech clusters, investors, and potential partners, facilitating in-person business development conversations and accelerated deal pacing.

Commercial Validation Revenue is in the early commercial range and the Boehringer Ingelheim collaboration provides third-party validation; opportunities include milestone-based licensing or co-development arrangements to monetize the TegMiner platform.